HPV16 E7 Polyclonal Antibody

$Sample: \r\nhela (Human) Cell Lysate at 30 ug\r\nmcf-7 (Human) Cell Lysate at 30 ug\r\nmda-mb-231 (Human) Cell Lysate at 30 ug\r\nsiha (Human) Cell Lysate at 30 ug\r\nrecombinant HPV16-E7 protein (bs-49101P) 100 ng\r\nrecombinant HPV16-E7 protein (bs-49101P) 50 ng\r\nPrimary: Anti-HPV16 E7 (bs-10202R) at 1\/1000 dilution\r\nSecondary: IRDye800CW Goat Anti-Rabbit IgG at 1\/20000 dilution\r\nPredicted band size: 11 kD\r\nObserved band size: 17-20 kD\r\nbs-49101P band size: 45 kD$

Sample: \r\nhela (Human) Cell Lysate at 30 ug\r\nmcf-7 (Human) Cell Lysate at 30 ug\r\nmda-mb-231 (Human) Cell Lysate at 30 ug\r\nsiha (Human) Cell Lysate at 30 ug\r\nrecombinant HPV16-E7 protein (bs-49101P) 100 ng\r\nrecombinant HPV16-E7 protein (bs-49101P) 50 ng\r\nPrimary: Anti-HPV16 E7 (bs-10202R) at 1\/1000 dilution\r\nSecondary: IRDye800CW Goat Anti-Rabbit IgG at 1\/20000 dilution\r\nPredicted band size: 11 kD\r\nObserved band size: 17-20 kD\r\nbs-49101P band size: 45 kD

$Lane 1: HPV16 E7 fusion protein (bs-49101P) 0.1ug Lysates; Lane 2: HPV16 E7 fusion protein (bs-49101P) 0.05ug Lysates. Probed with HPV16 E7 polyclonal Antibody, unconjugated (bs-10202R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.$

Lane 1: HPV16 E7 fusion protein (bs-49101P) 0.1ug Lysates; Lane 2: HPV16 E7 fusion protein (bs-49101P) 0.05ug Lysates. Probed with HPV16 E7 polyclonal Antibody, unconjugated (bs-10202R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.

$Hela cells were\u00a0fixed with 4% PFA for 10min at room temperature,permeabilized with\u00a090% ice-cold methanol for 20 min at -20\u2103,\u00a0and incubated in 5% BSA blocking buffer\u00a0for 30 min at room temperature. Cells were then stained with HPV16 E7 Polyclonal Antibody(bs-102020R)at 1:100 dilution\u00a0in blocking buffer and\u00a0incubated for 30 min at\u00a0room temperature,\u00a0washed twice with 2%BSA in PBS,\u00a0followed by\u00a0secondary antibody incubation\u00a0for 40 min\u00a0at\u00a0room temperature. Acquisitions of 20,000 events were performed.\u00a0Cells stained with primary antibody\u00a0(green), and isotype control (orange).$

Hela cells were\u00a0fixed with 4% PFA for 10min at room temperature,permeabilized with\u00a090% ice-cold methanol for 20 min at -20\u2103,\u00a0and incubated in 5% BSA blocking buffer\u00a0for 30 min at room temperature. Cells were then stained with HPV16 E7 Polyclonal Antibody(bs-102020R)at 1:100 dilution\u00a0in blocking buffer and\u00a0incubated for 30 min at\u00a0room temperature,\u00a0washed twice with 2%BSA in PBS,\u00a0followed by\u00a0secondary antibody incubation\u00a0for 40 min\u00a0at\u00a0room temperature. Acquisitions of 20,000 events were performed.\u00a0Cells stained with primary antibody\u00a0(green), and isotype control (orange).

Applications

WB
IHC-P
IF(IHC-P)

Reactivity

Virus

Overview
Catalog #	bs-10202R
Product Name	HPV16 E7 Polyclonal Antibody
Applications	WB, IHC-P, IF(IHC-P)
Reactivity	Virus
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from HPV16 E7 protein
Immunogen Range	11-70/98
Clonality	Polyclonal
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at -20°C for 12 months.
Target
Gene ID	1489079
Synonyms	E7; Human Papilloma Virus; Human papillomavirus type 16 E7; Human papillomavirus type 16 E7; Protein E7; Human Papillomavirus 16 E7; HPV16 E7; E7 protein HPV16; VE7_HPV16.
Background	Human papilloma viruses (HPVs) can be classified as either high risk or low risk according to their association with cancer. HPV16 and HPV18 are the most common of the high risk group while HPV6 and HPV11 are among the low risk types. Approximately 90% of cervical cancers contain HPV DNA of the high risk types. Mutational analysis have shown that the E6 and E7 genes of the high risk HPVs are necessary and sufficient for HPV transforming function. The specific interactions of the E6 and E7 proteins with p53 and pRB, respectively, correlate with HPV high and low risk classifications. The high risk HPV E7 proteins bind to pRB with a higher affinity than do the low risk HPV proteins, and only the high risk HPV E6 proteins form detectable complexes with p53 in vitro.
Application Dilution
WB	1:300-5000
IHC-P	1:200-400
IF(IHC-P)	1:50-200

Applications

Reactivity

Search our catalog of hundreds of thousands of products